Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03774459 | ANAVEX2-73 Study in Parkinson's Disease Dementia | PHASE2 | COMPLETED | 132 | — | — | Jul 9, 2018 | Sep 30, 2020 | Oct 22, 2020 | 25 | Australia, Spain |
Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test
Assess the safety and tolerability of ANAVEX2-73 compared to placebo
| Arm | Type | Description |
|---|---|---|
| High dose ANAVEX2-73 | EXPERIMENTAL | High dose ANAVEX2-73 |
| Mid dose ANAVEX2-73 | EXPERIMENTAL | Mid dose ANAVEX2-73 |
| Placebo oral capsule | PLACEBO_COMPARATOR | Placebo oral capsule |
| Name | Type | Description |
|---|---|---|
| High dose ANAVEX2-73 | DRUG | Active oral capsule |
| Mid dose ANAVEX2-73 | DRUG | Active oral capsule |
| Placebo oral capsule | DRUG | Placebo oral capsule |
Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease (PD) consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria. * Diagnosis of probable PD dementia (PDD) according to the Movement Disorder Society Task Force clinical diagnostic criteria. * Montreal Cognitiv...